胸腺肽α1联合恩替卡韦对乙肝肝硬化患者乙型肝炎e抗原的影响

The Effect of Combination of Thymosinα 1 and Entecavir on the HBeAg of Patients with HBV-liver Cirrhosis

目的:分析胸腺肽α1联合恩替卡韦治疗对于乙肝肝硬化患者的乙型肝炎e抗原(HBe Ag)的影响。方法:选取2013年4月至2016年4月于哈尔滨医科大学附属第二医院感染二科住院和门诊复查的患者50例,随机将患者分为两组,应用胸腺肽α1联合恩替卡韦治疗的患者为实验组,共25例,单一应用恩替卡韦治疗的患者为对照组,共25例。比较两组患者治疗前和治疗半年后的肝功能、乙肝病毒载量以及HBe Ag定量。结果:治疗半年后,实验组患者的肝功能和乙肝病毒载量与对照组比较无明显差异(P>0.05),实验组的HBe Ag量明显低于对照组(P<0.05)。结论:胸腺肽α1联合恩替卡韦可以有效的降低HBe Ag量,促进e抗原转阴,减少病毒复制。

Objective： To analyze the effect of combination of thymosinα1 with entecavir on the HBe Ag of patients with HBV-liver cirrhosis. Methods： 50 cases of patients in the hospitalized and outpatient sections of Second Affiliated Hospital of Harbin Medical University Communicable Diseases Department Two from April, 2013 to April, 2016 were selected and randomly divided into two groups.25 cases of patients received the combination of Thymosinα1 with Entecavir were considered as the experimental group and 25 cases of patients received single-agent Entecavir were considered as the control group. The liver function, levels of HBV DNA in serum and HBe Ag quantity after half a year’s treatment were compared between two groups. Results： There was no significant difference in the liver function, levels of HBV DNA in serum between two groups（P〉0.05） after half a year’s treatment, while the HBe Ag quantity of experimental group was obviously lower than that of the control group（P〈0.05）. Conclusions： The combination of thymosinα1 with entecavir could effectively decrease the HBe Ag quantity and promote HBe Ag to become negative reducing virus copy.